The Short Version
The claim is largely accurate. Large randomized trials — most notably SELECT — have demonstrated that semaglutide reduces major cardiovascular events (CV death, nonfatal MI, nonfatal stroke) in patients with established cardiovascular disease and obesity but without diabetes. Tirzepatide has shown benefits in heart failure with preserved ejection fraction. However, the strongest evidence applies specifically to overweight/obese patients with existing CVD, not all cardiovascular populations, and some endpoints like overall mortality remain neutral. The claim slightly overgeneralizes but is well-supported by current evidence.